From respiratory to neurological diseases to various forms of disability. These are the hyper-fragile subjects for whom a third booster dose of the anti-Covid vaccine will be provided. This is foreseen in the new circular ‘Update of the indications on the administration of additional doses and “booster” doses as part of the anti-SARS-CoV-2 / COVID-19 vaccination campaign “issued by the Ministry of Health.
For the purposes of the plan for administering a booster dose, the circular reads, “it will be possible to progressively offer a further dose of Cominarty vaccine (authorized by EMA for this indication) to people with high frailty, regardless of age, and to all those who are 60 years of age or older, provided that at least 6 months have passed since the completion of the primary vaccination cycle “.
The concomitant / pre-existing conditions of high fragility, with indication of the booster dose of anti SARS-CoV-2 / COVID-19 vaccine, are: respiratory diseases (Idiopathic pulmonary fibrosis; Respiratory diseases requiring oxygen therapy); cardiovascular diseases (Heart failure in advanced class; Patients post-cardiogenic shock); neurological diseases (Amyotrophic lateral sclerosis and other motor neuron diseases; Multiple sclerosis; Muscular dystrophy; Infantile cerebral palsy; Myasthenia gravis; Dysimmune neurological disorders). And again: diabetes and other severe endocrinopathies (Type 1 diabetes; Type 2 diabetes treated with at least 2 diabetes drugs or with complications; Addison’s disease; Panhypopituitarism); liver disease (liver cirrhosis); cerebrovascular diseases (Cerebral ischemic-hemorrhagic event with impairment of neurological and cognitive autonomy; Stroke in 2020-21; Stroke before 2020 with ranking ≥ 3); Hemoglobinopathies (Thalassemia major; Sickle cell anemia; Other severe anemias); other aptologies (Cystic fibrosis; Down syndrome; Severe obesity); Physical, sensory, intellectual and mental disability (Seriously disabled pursuant to law 104/1992 art. 3 paragraph 3).
breaking latest news © Copyright ANSA